Latest Biotech News

Bio-Gene Technology Limited has addressed ASX concerns over the timing of its announcement on promising Flavocide efficacy data, confirming compliance with continuous disclosure rules after receiving final presentation materials from Purdue University.

Imagion Biosystems has completed the second tranche of its $3.5 million placement, raising $2.85 million to advance its proprietary MagSense® imaging technology targeting breast, prostate, and ovarian cancers.

Nyrada Inc. has announced successful Phase I trial results for its lead drug candidate Xolatryp, confirming safety and pharmacokinetics that pave the way for a Phase IIa trial targeting heart attack patients next year.

Arovella Therapeutics has received a $3.21 million R&D tax incentive refund, bolstering its financial position as it prepares to initiate first-in-human trials for its lead cell therapy, ALA-101.

Noxopharm Limited has secured an extension on $2.6 million of convertible notes and obtained a $1.25 million unsecured loan to bolster working capital, pending shareholder approval.

Starpharma has entered a significant collaboration with Genentech to develop dendrimer-drug conjugates for oncology, securing an upfront payment and potential milestone earnings exceeding half a billion dollars.

Starpharma has entered a landmark collaboration with Genentech to develop innovative cancer therapies using its proprietary DEP® platform, securing $5.5 million upfront and potential milestones exceeding $560 million.

PYC Therapeutics has restructured its Board and executive team to steer the company through pivotal clinical milestones expected by the end of 2027. The changes signal a strategic push toward late-stage development of its RNA-based drug candidates.

Island Pharmaceuticals has won a crucial FDA Type C meeting to discuss fast-tracking its antiviral Galidesivir for Marburg virus treatment, with written feedback expected by November.

Neurizon Therapeutics has locked in a significant R&D tax incentive advance covering overseas and domestic development costs for its lead ALS drug candidate NUZ-001, accelerating its clinical progress with a $5.6 million rebate expected in 2025.

Neurizon Therapeutics has raised $5 million through an institutional placement to advance its lead ALS drug candidate NUZ-001 into a pivotal clinical trial, pending FDA clearance. The capital injection also supports manufacturing and pre-clinical development efforts.

PYC Therapeutics announces the resignation of CEO Dr Rohan Hockings, appointing Chairman Alan Tribe as interim Managing Director while searching for a permanent replacement.